Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Front Oncol
.
2017 Mar 13:7:31.
doi: 10.3389/fonc.2017.00031.
eCollection 2017.
Author
Nabil F Saba
1
Affiliation
1
Hematology and Medical Oncology, Winship Cancer Institute of Emory University , Atlanta, GA , USA.
PMID:
28348975
PMCID:
PMC5346538
DOI:
10.3389/fonc.2017.00031
No abstract available
Keywords:
EGFR; HER3 inhibitors; Nrg1; cetuximab; squamous cell carcinoma of the head and neck.
Publication types
Comment